the immune system; pathogenesis of neuroimmune diseases




Zsolt Illes


Department of Neurology Odense University Hospital University of Southern Denmark

novelties in neuroimmunology, 2014

- novel treatments in MS: oral, biological
- anti-AQP4 in NMO, then anti-MOG in NMO
- novel pathogenic antibodies in myasthenia gravis: anti-Lrp4, anti-agrin
- antibody-mediated encephalitis and epilepsy syndromes

immune system





components of the immune system



limited (pattern)

linear

no

random

no

complement phagocytes, NK, DC FcR, CR, cytokine rec antigen specificity

propagation, enhancement

memory

interaction with antigen

latency

soluble cellular receptors



yes

exponential


yes

selective

yes


antibodies lymphocytes BCR, TCR

autoimmunity: compartments




susceptibility, tolerance

threshold liability model: gene-environment



vitamin D levels: genes and environment


Laursen, JH, Mult Scler, 2014



levels: systems biology approach

epigenetic modifications:

- do not involve a change in DNA sequence
- alter gene expression
- heritable changes, environmental effects
- DNA methylation, histone modification, nucleosome position, non-coding RNA





Andrew Z. Fire

microRNA






Craig C. Mello

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello, CC "Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*" 1998, *Nature* 391 (6669): 806–811


Dr. Mello recounted the phone call that he received announcing that he had won the prize.

He recalls that it was shortly after 4:30 am and he had just finished checking on his daughter, and returned to his bedroom. The phone rang (or rather the green light was blinking) and his wife told him not to answer, as it was a crank call. Upon questioning his wife, she revealed that it had rung while he was out of the room and *someone was playing a bad joke on them* by saying that he had won the Nobel prize. When he told her that they were actually announcing the Nobel prize winners on this very day, he said "her jaw dropped."


microRNA: complexity



self-tolerance: protection against autoimmunity



antigen presentation: MHC and T cell receptor




MHC I, MHC II, MHC III: chromosome 6

classical complement C2 C4 cytokine TNF- α and β heat shock proteins

III

brain:

C1q and C3 tag synapses for elimination TNF- α regulates expression of AMPARs, incresaes connectivity hsp: chaperons, elimination of misfolding proteins



I on all nucleated cell

presented peptides: **intracellular** MHC-peptide monitored by **CD8+ Tc** binds to inhibitory receptors of **NK**


brain:

modulate synaptic plasticity (negatively NMDAR function and AMPAR trafficking) expression regulated by neuronal activity on antigen presenting cells II presented peptides: extracellular MHC-peptide monitored by CD4+ Th


brain:

microglia, astrocyte, perivascular monocyte


central tolerance



antigen in the thymus and autoimmune susceptibility



T cell activation and signals




APC: antigen presenting cell

hyper-IgM syndrome

19-year old male


- CD40L deficiency
- hyper-IgM syndrome
- monthly IVIG since age of 3

T cell activation and signals




APC: antigen presenting cell

PML – progressive multifocal leukoencephalopathy




19-year old male

- CD40L deficiency
- hyper-IgM syndrome
- monthly IVIG since age of 3
- concentration and memory problems
- progressive hemiparesis
- normal CSF
- coma in 6 weeks




immune response and autoimmunity




break in self-tolerance leads to autoimmunity

immune response to self- vs. foreign-antigens



immune response to self- vs. foreign-antigens



interference with IL23-IL17


agent	target	company	clinical trial
ixekizumab	IL-17A	Eli Lilly	psoriasis, RA
secukinumab	IL-17A	Novartis	MS (II) and many
brodalumab	IL-17RA	Amgen, MedImmune	psoriasis, CD, asthma
ABT-122	IL-17A and TNF	Abbott, AbbVie	RA
ustekinumab	p40 IL-12 and IL-23	Johnson&Johnson, Janssen Biotech	MS (II) and many
briakinumab	p40 IL-12 and IL-23	Abbott	MS (II), CD, psoriasis
tildrakizumab	IL-23p19	Merck	psoriasis
guselkumab	IL-23p19	Johnson&Johnson, Janssen Biotech	psoriasis, RA
AMG-139	IL-23p19	Amgen, MedImmune	psoriasis, CD
LY-3074828	IL-23p19	Eli Lilly	psoriasis
BI-655066	IL-23p19	Boehringer Ingelheim	psoriasis, CD, AS

CD: Crohn's disease, RA: rheumatoid arthritis, AS: ankylosing spondylitis

microbiome

Am J Pathol 2008, PNAS 2011, Nature 2011

microbome: microbial ecosystem (microbiota) plus its entire genetic content



absence of microbial flora: milder EAE (MOG)

microbiota in early infancy

hygiene hypothesis:

lack of microbial exposure – immune dysregulation (Th2) *microflora hypothesis*:

microbiota alteration – disrupt immune tolerance *vanishing microbiota hypothesis:*

changes in microbiota – allergy/immune diseases

postnatal

- feeding (breast/bottle)
- solid food introduction
- pre/probiotics
- antibiotics


perinatal

- delivery (vaginal/cesarean)
- gestation time (preterm/term)
- maternal nutrition (pre/probiotics)
- antibiotics


prenatal

- intrauterine colonization
- host genetics
- maternal nutrition (pre/probiotics)
- antibiotics


molecular mimicry




the complement cascade




the complement cascade



B cell functions




effect of Abs: treatment consideration!



when does autoimmunity start?





THANK YOU

